全膝关节置换术中止血带使用与患者报告结局的关联:一项多中心比较
基于PEPPER试验的多中心比较纳入5,684例初次全膝关节置换术患者,其中使用止血带组4,866例(85.6%),未使用止血带组818例(14.4%)。仅在术后1个月时,止血带组达到KOOS JR最小临床重要差异的患者比例显著高于未使用止血带组(55.4% vs 47.9%),该差异在3个月和6个月时消失;两组在PROMIS-PH10、NPRS、阿片类药物消耗、手术时间、住院时长、伤口相关并发症及再入院方面均无差异。多变量分析显示止血带使用对患者报告结局指标无临床意义的影响。
要点
- 术后1个月止血带组达到KOOS JR最小临床重要差异的患者比例显著高于未使用止血带组(55.4% vs 47.9%),3个月和6个月时差异消失。
- 两组在PROMIS-PH10和NPRS达到最小临床重要差异的患者比例及各时间点评分均无差异。
- 两组在阿片类药物消耗、手术时间、住院时长、伤口相关并发症及再入院方面均无差异。
核心结论
- 与不使用止血带相比,使用止血带与术后1个月更多患者达到KOOS JR的最小临床重要差异相关,该差异在3个月和6个月时消失。
- 术后1、3、6个月,使用止血带与不使用止血带的初次全膝关节置换术患者在阿片类药物消耗、医疗资源利用或并发症方面无差异。
- 多变量分析显示止血带使用对患者报告结局指标无临床意义的影响。
- 关节置换外科医生可在术前与患者讨论止血带使用时参考这些数据,内容涉及外科医生的偏好及其对术后功能可能的影响。
研究设计与样本
- 作为PEPPER试验的一部分,识别5,684例接受初次全膝关节置换术的患者,其中4,866例(85.6%)使用止血带(YT组),818例(14.4%)未使用止血带(NT组)。
- 队列以女性为主(60.8%)、白人(77%)、非西班牙裔或拉丁裔族裔(96.8%),患者平均年龄64.6±9.2岁。
- 主要结局为膝关节损伤与骨关节炎结局评分-关节置换版(KOOS JR)、患者报告结局测量信息系统身体健康简表(PROMIS-PH10)和数字疼痛评定量表(NPRS),于术前及术后1、3、6个月采集。
- 次要结局为住院时长、出院去向、镇痛药消耗和术后并发症。
- 采用多变量分析评估止血带使用与全膝关节置换术后患者报告结局指标之间的关联。
主要发现
- 达到KOOS JR最小临床重要差异的患者比例仅在术后1个月时存在显著差异(YT组55.4% vs NT组47.9%),3个月和6个月时该差异消失。
- 两组在PROMIS-PH10或NPRS达到最小临床重要差异的患者比例在任何时间点均无差异。
- 两组在KOOS JR、PROMIS-PH10和NPRS评分方面任何时间点均无差异。
- 两组在阿片类药物消耗、手术时间、住院时长、伤口相关并发症或术后再入院方面均无差异。
关键数值与推荐
- 达到KOOS JR最小临床重要差异的患者比例:术后1个月YT组55.4% vs NT组47.9%,差异显著。
- 达到KOOS JR最小临床重要差异的患者比例:术后3个月和6个月两组差异消失。
- 达到PROMIS-PH10或NPRS最小临床重要差异的患者比例:任何时间点两组均无差异。
- 证据等级:治疗性III级。
临床怎么用
- 关节置换外科医生可在术前与患者讨论止血带使用时参考这些数据,内容涉及外科医生的偏好及其对术后功能可能的影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Total knee arthroplasty (TKA) is one of the most commonly performed elective procedures in North America. While advancements have been made in patient optimization, surgical technique, and implant design, tourniquet use remains a contentious issue as it relates to patient outcomes and postoperative experience. METHODS: As part of the PEPPER trial, we identified 5,684 patients who underwent primary TKA, of whom 4,866 (85.6%) underwent surgery with a tourniquet (the YT group) and 818 (14.4%) underwent surgery without a tourniquet (the NT group). The cohort was predominantly female (60.8%), White (77%), and of an ethnicity other than Hispanic or Latino (96.8%). The mean age of the patients was 64.6 ± 9.2 years. The primary outcomes were the Knee injury and Osteoarthritis Outcome Score, Joint Replacement (KOOS JR); Patient-Reported Outcomes Measurement Information System Physical Health Summary (PROMIS-PH10); and numeric pain rating scale (NPRS), which were captured preoperatively and at 1, 3, and 6 months postoperatively. The secondary outcomes were length of stay, discharge disposition, analgesic consumption, and postoperative complications. Multivariable analysis was performed to assess the associations between tourniquet use and patient-reported outcome measures (PROMs) following TKA. RESULTS: The percentages of patients achieving the minimal clinically important difference (MCID) for the KOOS JR were significantly different at 1 month only (YT, 55.4%; NT, 47.9%). This difference disappeared at 3 and 6 months. There was no difference between the YT and NT groups in terms of the percentage of patients achieving the MCID for the PROMIS-PH10 or NPRS at any time point. There were no differences between the YT and NT groups at any time point with respect to the KOOS JR, PROMIS-PH10, and NPRS. There were no differences in opioid consumption, operative time, length of stay, wound-related complications, or readmissions postoperatively. CONCLUSIONS: Tourniquet use was associated with more patients achieving the MCID for the KOOS JR at 1 month compared with no tourniquet use. This difference disappeared at 3 and 6 months. At 1, 3, and 6 months, there were no differences in opioid consumption, health-care utilization, or complications between patients undergoing TKA with a tourniquet versus without a tourniquet. Tourniquet use did not have a clinically meaningful impact on PROMs in the multivariable analysis. Arthroplasty surgeons may use these data during preoperative discussions with patients regarding tourniquet use as it relates to the surgeon's preference and how it could influence postoperative function. LEVEL OF EVIDENCE: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
引用
- Gibbs B, Sniderman J, Mohammed S, et al. Association Between Tourniquet Use and Patient-Reported Outcomes Following Total Knee Arthroplasty: A Multicenter Comparison. J Bone Joint Surg Am. 2025. PMID: 40112083. doi:10.2106/JBJS.24.00266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。